David P. Meeker - 03 Jun 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Reporting relationship: President and CEO, Director
Issuer ticker: RYTM
Reported as of: 03 Jun 2025
Net transaction value: -$2,637,118
SEC form: 4
Accepted by SEC: 05 Jun 2025, 16:16:07 UTC
Prior SEC filing: 19 Feb 2025
Next SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Stephen Vander Stoep, Attorney-in-Fact for David Meeker

Key filing fact

David P. Meeker filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 05 Jun 2025.

Key facts

This page summarizes David P. Meeker's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2025, 16:16.

Change

Previous filing in this sequence was filed on 19 Feb 2025.
Current net transaction value: -$2,637,118.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001385155 Primary reporting owner

Meeker David P

Relationship: President and CEO, Director
Address: C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON
Signature: /s/ Stephen Vander Stoep, Attorney-in-Fact for David Meeker
Signature date: 05 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RYTM transaction

Common Stock

Options Exercise

Transaction value: $200,216
Shares: +43,620
Change %: +22%
Price: $4.59
Shares after: 245,445
Date: 03 Jun 2025
Ownership: Direct
Footnotes: F1

RYTM transaction

Common Stock

Sale

Transaction value: $2,819,358
Shares: -43,346
Change %: -18%
Price: $65.04
Shares after: 202,099
Date: 03 Jun 2025
Ownership: Direct
Footnotes: F2, F3

RYTM transaction

Common Stock

Sale

Transaction value: $17,975
Shares: -274
Change %: -0.14%
Price: $65.60
Shares after: 201,825
Date: 03 Jun 2025
Ownership: Direct
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYTM transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -43,620
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 03 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 43,620
Exercise price: $4.59
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Includes 544 additional shares acquired under the Issuer's Employee Stock Purchase Plan.

Footnote F2

The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 plan adopted by the Reporting Person on March 3, 2025.

Footnote F3

The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $64.59 to $65.58 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.60 to $65.61 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

The stock option is fully vested.